Stefanie Desmet

Stefanie Desmet

Auto-generated profile, based on publicly available information

Stefanie Desmet

Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
SDStefanie Desmet
Stefanie Desmet
EWEric Van Wijngaerden
Eric Van Wijngaerden
JMJohan Maertens
Johan Maertens
JVJan Verhaegen
Jan Verhaegen
EVEric Verbeken
Eric Verbeken
KLKatrien Lagrou
Katrien Lagrou
(1-3)-β- d -Glucan (BG) reactivity was tested in serum samples from 28 patients with human immunodeficiency virus infection or a hematological malignancy and Pneumocystis jirovecii pneumonia (PCP) and 28 control patients. The sensitivity and specificity of BG detection with the Fungitell assay for PCP were 100 and 96.4%, respectively, using a cutoff value of 100 pg/ml. Serum BG testing looks promising for the noninvasive diagnosis of PCP. Our data suggest that a higher cutoff value for the diagnosis of PCP than for the diagnosis of invasive aspergillosis or candidiasis could be used safely and will improve the specificity of the test.

1 November 2017 in Research in Microbiology
Verified
Journal Article
Closed access
MCMathieu Cauchie
Mathieu Cauchie
SDStefanie Desmet
Stefanie Desmet
Katrien LagrouKatrien Lagrou
Katrien Lagrou

1 January 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SDStefanie Desmet
Stefanie Desmet
KLKatrien Lagrou
Katrien Lagrou
CWChloé Wyndham-Thomas
Chloé Wyndham-Thomas
TBToon Braeye
Toon Braeye
JVJan Verhaegen
Jan Verhaegen
SBSophie Blumental
Sophie Blumental

1 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
MQMaria Garcia Quesada
Maria Garcia Quesada
YYYangyupei Yang
Yangyupei Yang
JBJulia Bennett
Julia Bennett
KHkyla hayford
kyla hayford
SZScott L. Zeger
Scott L. Zeger
TTthe PSERENADE Team
the PSERENADE Team
Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.

2 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
MKMaria Deloria Knoll
Maria Deloria Knoll
JBJulia Bennett
Julia Bennett
MQMaria Garcia Quesada
Maria Garcia Quesada
EKE. Wangeci Kagucia
E. Wangeci Kagucia
MPMeagan Peterson
Meagan Peterson
TTthe PSERENADE Team
the PSERENADE Team
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.

29 January 2024 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
MPMarijke Peetermans
Marijke Peetermans
VMVeerle Matheeussen
Veerle Matheeussen
CMCedric Moerman
Cedric Moerman
FRFréderic De Rydt
Fréderic De Rydt
STSabine Thieren
Sabine Thieren
PJPhilippe G. Jorens
Philippe G. Jorens
Recent alerts have highlighted an increase in group A streptococcal (GAS) infections since 2022 in Europe and the United States. Streptococcus pyogenes can cause limited skin or mucosal disease, but can also present as severe invasive disease necessitating critical care. We performed a multicenter retrospective study of patients with GAS infections recently admitted to Belgian intensive care units (ICUs) since January 2022. We describe patient characteristics and investigate the molecular epidemiology of the S. pyogenes strains involved. Between January 2022 and May 2023, a total of 86 cases (56 adults, 30 children) with GAS disease were admitted to critical care in the university hospitals of Leuven, Antwerp and Liège. We noted a strikingly high incidence of severe community-acquired pneumonia (sCAP) (45% of adults, 77% of children) complicated with empyema in 45% and 83% of adult and pediatric cases, respectively. Two-thirds of patients with S. pyogenes pneumonia had viral co-infection, with influenza (13 adults, 5 children) predominating. Other disease presentations included necrotizing fasciitis (23% of adults), other severe skin/soft tissue infections (16% of adults, 13% of children) and ear/nose/throat infections (13% of adults, 13% of children). Cardiogenic shock was frequent (36% of adults, 20% of children). Fifty-six patients (65%) had toxic shock syndrome. Organ support requirements were high and included invasive mechanical ventilation (77% of adults, 50% of children), renal replacement therapy (29% of adults, 3% of children) and extracorporeal membrane oxygenation (20% of adults, 7% of children). Mortality was 21% in adults and 3% in children. Genomic analysis of S. pyogenes strains from 55 out of 86 patients showed a predominance of emm1 strains (73%), with a replacement of the M1global lineage by the toxigenic M1UK lineage (83% of emm1 strains were M1UK). The recent rise of severe GAS infections (2022–23) is associated with introduction of the M1UK lineage in Belgium, but other factors may be at play—including intense circulation of respiratory viruses and potentially an immune debt after the COVID pandemic. Importantly, critical care physicians should include S. pyogenes as causative pathogen in the differential diagnosis of sCAP.